Faster, more durable tissue regeneration for equine athletes
CellDrop Bio is supporting Veterinarians through development of biotherapeutics to heal equine musculoskeletal injuries faster and reduce the chance of re-injury.
Learn More
CellDrop Bio is supporting Veterinarians through development of biotherapeutics to heal equine musculoskeletal injuries faster and reduce the chance of re-injury.
Learn MoreHydrogel microengineering is central to both biotherapeutic and rapid testing technologies.
view technology
This seed round complements state and federal grant funding to advance CellDrop's hydrogel encapsulated allogeneic cell therapy, reducing it's time to market.
learn moreSuccessful completion of CellDrop's Phase I NSF STTR yielded promising results demonstrating safety and improved efficacy of their encapsulated therapy in a rodent model of tendon injury. To build on this success, they have submitted a Phase II NSF STTR funding a preclinical trial of their flagship therapeutic in equine superficial digital flexor tendon injuries.
learn moreThere remains an unmet need for accurate, inexpensive, point of care testing. To meet this need, CellDrop is developing rapid lateral flow assays for both COVID-19 and a variety of other antigens, using our hydrogel microengineering technology.
learn moreThis Phase I STTR Project will address the problem of suspensory ligament and superficial digital flexor tendon injuries in performance horses by developing an efficacy enhanced stem cell biotherapeutic.
learn more